Jul 02, 2026
15 MIN READ

How Much Weight Per Week Do You Lose on Zepbound?

Zepbound users typically lose 0.5 to 1.5 pounds per week during the initial 16-week titration phase, with greater losses occurring in later months. Individual results depend on starting weight, baseline metabolism, diet, and genetic peptide sensitivity.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jul 02, 2026
15 MIN READ

how much weight per week do you lose on zepbound? — PlexusDx GLP-1 education

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide) is a dual-action GLP-1 and GIP receptor agonist that works by reducing hunger signals and increasing feelings of fullness. Clinical trials show participants lose an average of 21% of their body weight over 68 weeks—but weekly progress varies significantly based on personal factors and how your body responds to the medication.

Typical Weekly Weight Loss Timeline on Tirzepatide

Most people taking tirzepatide lose between 0.5 and 1.5 pounds per week during the first four months as their dose gradually increases from 2.5 mg to the therapeutic range. Weight loss is typically slower in weeks 1–4 because the starting dose is subtherapeutic; meaningful appetite suppression increases as dosing climbs. By weeks 12–16, when patients reach their maintenance dose, weekly losses often accelerate to 1 to 2 pounds as the full pharmacological effect becomes established.

After the titration phase (weeks 16 onward), loss rate often plateaus or slows compared to the rapid early months. This is expected and normal—your body has adjusted to the medication, and caloric deficit becomes the primary driver of continued weight loss. Some individuals see steady 0.5–1 pound weekly losses indefinitely, while others experience natural plateaus that require diet or activity adjustments to overcome.

Total weight loss over 68 weeks in the SURMOUNT trials averaged 21–23% of starting body weight for participants on the highest doses. This translates to roughly 50–100+ pounds for a 250-pound person, but distributed unevenly across the timeline—front-loaded losses in months 1–4, then more gradual progress through month 12 and beyond.

Factors That Influence Your Weekly Weight Loss Rate

Starting body weight is the single strongest predictor of early weight loss speed. Individuals with higher baseline weight tend to lose more pounds per week initially because a larger caloric deficit is created at the same dose level. Conversely, someone closer to their goal weight may see slower weekly progress despite meaningful percentage-based fat loss.

Genetic peptide sensitivity—measured through variants in GLP1R, GIPR, FTO, and MC4R pathways—significantly affects how well your body responds to tirzepatide. People with favorable genetic predispositions in these appetite and metabolic genes may experience stronger appetite suppression and faster initial losses. PlexusDx's Precision Peptide Genetic Test identifies 14 pathways and 49 peptides to predict individual medication response, helping clinicians optimize dosing and timeline expectations.

Diet quality and adherence matter more as tirzepatide reaches steady-state dosing. Even with robust appetite suppression, consuming calorie-dense, highly processed foods can slow weight loss or stall progress. Protein intake, meal timing, and hydration status also influence weekly outcomes. Physical activity, sleep quality, and stress management further modulate the rate at which the body mobilizes stored fat.

How Compounded Tirzepatide Dosing Affects Your Results

PlexusDx offers compounded tirzepatide injection starting at $249 per month across all dose levels, ensuring your dose can increase as needed without price increases—a model designed to support safe titration and optimal outcomes. Doses typically begin at 2.5 mg weekly and increase by 2.5 mg every 4 weeks until reaching a therapeutic target (usually 10–15 mg weekly for weight loss). This gradual approach minimizes nausea and side effects while allowing your body to adapt.

Compounded tirzepatide from licensed 503A pharmacies meets the same quality and sterility standards as branded Zepbound but provides cost savings and broader access across all 50 states without insurance requirements. Some individuals respond faster to tirzepatide than semaglutide alone, and genetic testing can help identify whether you're a candidate for single-agent GLP-1 or dual GLP-1/GIP therapy. Your clinician's dose escalation schedule directly influences weekly weight loss patterns, with faster titration potentially accelerating initial losses but raising side effect risk.

Realistic Expectations and Long-Term Weight Loss Sustainability

Expecting 2–3 pounds per week every week is unrealistic and sets up disappointment. Even during peak loss months, weekly variability is normal—you may drop 3 pounds one week and 0.5 pounds the next due to water retention, hormonal cycles, and scale measurement error. Tracking monthly or 4-weekly averages provides a more accurate picture than obsessing over daily or weekly fluctuations.

Sustained weight loss on tirzepatide requires long-term medication adherence. Clinical data suggests that stopping tirzepatide leads to weight regain in most individuals, with 50% of lost weight returning within one year off the medication. This reflects the chronic nature of weight dysregulation and appetite control—tirzepatide is a treatment, not a cure. Combining medication with permanent lifestyle changes (structured eating patterns, regular movement, stress reduction) creates the best foundation for maintaining losses after treatment ends or dosing is optimized downward.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What's the average weight loss per week on Zepbound in the first month?

Most people lose 0.5 to 1 pound per week during the first month, partly because the starting dose (2.5 mg) is sub-therapeutic for appetite suppression. Meaningful weekly losses accelerate once dosing reaches 5–7.5 mg by weeks 4–8. Individual variation is significant and depends on starting weight and metabolism.

How does tirzepatide compare to semaglutide for weekly weight loss?

Tirzepatide (a dual GLP-1/GIP agonist) typically produces faster and greater total weight loss than semaglutide monotherapy in clinical trials—roughly 5–10% more weight loss over the same timeframe. This means weekly losses may be 0.1–0.3 pounds faster on average, though individual responses vary. PlexusDx offers both options; genetic testing can help predict which suits your peptide pathways best.

Does PlexusDx tirzepatide cost more if I increase my dose?

No. PlexusDx compounded tirzepatide injection starts at $249 per month flat across all dose levels—your dose can increase as needed without price changes. This pricing model supports safe, personalized titration without financial barriers to reaching your therapeutic target.

What happens to weekly weight loss if I stop tirzepatide?

Weight regain typically begins within weeks of stopping tirzepatide, with most people recovering approximately 50% of lost weight within one year. This underscores that medication is a long-term tool for appetite regulation. Combining tirzepatide with sustainable lifestyle habits maximizes the chance of maintaining losses long-term.

Can genetic testing predict my weekly weight loss on tirzepatide?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) analyzes 14 metabolic and appetite pathways—including GLP1R, GIPR, FTO, and MC4R variants—to predict individual medication response and efficacy. Favorable genetic profiles often correlate with faster initial weight loss and stronger appetite suppression, helping your clinician optimize dosing and timeline expectations.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves